Monopar Therapeutics (MNPR) risk factors, FY2024 10-K

Risks Related to Our Financial Condition and Capital Requirements

1. 01We have a limited operating history, expect to incur significant operating losses, and have a high risk of never being profitable
2. 02We may need to raise additional funding or find one or more suitable pharmaceutical partners to continue to advance our clinical programs; finance our regulatory, precommercial and commercial activities; and support our preclinical studies
3. 03higher than expected costs to protect our intellectual property portfolio or otherwise pursue our intellectual property strategy
4. 04Market variables, such as inflation of product costs, labor rates and fuel, freight and energy costs, tariffs, as well as geopolitical events could likely cause us to suffer significant increases in our operating and administrative expenses
5. 05Unstable market and economic conditions may have serious adverse consequences on our ability to raise funds, which may cause us to delay, restructure or cease our operations
6. 06Impacts from prolonged remote work arrangements, such as increased cybersecurity risks

Risks Related to Clinical Development and Regulatory Approval

1. 07There are risks and uncertainties associated with our recently acquired ALXN1840 program which could result in delays in development or in gaining marketing approval, if at all, and such delays will negatively impact our financial condition
2. 08In the near term, we will be focusing on assembling a regulatory package and submitting an NDA. These activities will provide clarity on the additional capital needed for the program
3. 09Radiopharmaceuticals are a relatively novel approach to cancer imaging and treatment, which may create significant and potentially unpredictable challenges for them
4. 10establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of our novel radiopharmaceutical imaging and therapeutics
5. 11We do not have and may never have any approved products on the market. Our business is highly dependent upon receiving approvals from various U.S., Australian, and international governmental agencies and will be severely harmed if we are not granted approval to manufacture and sell our product candidates
6. 12Our products may fail to be more effective than current therapies, or to be effective at all
7. 13Patients involved in our clinical trials may suffer severe adverse side effects even up to death, whether as a result of treatment with our products, the withholding of such treatment, or other reasons which may not include the effects of our treatment (whether within or outside of our control)
8. 14Even if we are successful in our clinical trials, required governmental approvals may still not be obtained or, if obtained, may not be maintained
9. 15Any success we may achieve at a given stage of our clinical trials does not guarantee that we will achieve success at any subsequent stage, including without limitation final FDA or other regulatory organizations’ approval
10. 16Even if we complete the clinical trials we discussed with the FDA or TGA, there is no guarantee that at the time of submission the FDA or TGA will accept our NDA or BLA based on the trials discussed
11. 17As a company, we have never completed a clinical trial and have limited experience in completing regulatory filings and any delays in regulatory filings could materially affect our financial condition
12. 18We, or any future collaborators, may not be able to obtain and maintain orphan drug exclusivity for our product candidates in the U.S. and Europe
13. 19If serious adverse or undesirable side effects are identified during the development of our product candidates, we may abandon or limit our development or commercialization of such product candidates
14. 20If we experience delays or difficulties in the enrollment of subjects to our clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented, which could materially affect our financial condition
15. 21potential long-term effects of COVID-19, any resurgences thereof or any future pandemics
16. 22It is uncertain whether product liability insurance will be adequate to address product liability claims, or that insurance against such claims will be affordable or available on acceptable terms in the future
17. 23If the market opportunities for our current and potential future drug candidates are smaller than we believe they are, our ability to generate product revenues will be adversely affected and our business may suffer

Risks Related to Our Reliance on Third Parties

1. 24Corporate, non-profit, and academic collaborators may take actions (including lack of effective actions) to delay, prevent, or undermine the success of our products
2. 25The termination of third-party licenses could adversely affect our rights to important compounds or technologies
3. 26Data provided by collaborators and other parties upon which we rely have not been independently verified and could turn out to be inaccurate, misleading, or incomplete
4. 27In certain cases, we may need to rely on a single supplier for a particular manufacturing material or service, and any interruption in or termination of service by such supplier could delay or disrupt the commercialization of our products
5. 28We rely on a limited number of contracted manufacturing plants. If we need to enlist new or different contract manufacturers, it will delay our ALXN1840 and MNPR-101 radiopharmaceutical programs and may increase the costs of our clinical trials and/or regulatory efforts

Risks Related to Commercialization of Our Product Candidates

1. 29We have no experience as a company in commercializing any product. If we fail to obtain commercial expertise, upon product approval by regulatory agencies, our product launch and revenues could be delayed
2. 30We have not yet undertaken any marketing efforts, and there can be no assurance that future anticipated market testing and analyses will validate our marketing strategy. We may need to modify the products, or we may not be successful in either developing or marketing those products
3. 31If we are unable to establish relationships with licensees or collaborators to carry out sales, marketing, and distribution functions or to create effective marketing, sales, and distribution capabilities, we will be unable to market our products successfully
4. 32Commercial success of our product candidates will depend on the acceptance of these products by physicians, payers, and patients
5. 33Our ability to provide acceptable and compelling evidence of safety and efficacy
6. 34Our products may not be accepted for reimbursement or adequately reimbursed by third-party payers
7. 35The effects of economic and political pressure to lower pharmaceutical prices are a major threat to the economic viability of new research-based pharmaceutical products, and any significant decrease in drug prices could materially and adversely affect our prospects
8. 36Negotiated prices for our products covered by a Part D prescription drug plan and other government programs will be lower than the prices we might otherwise obtain

Risks Related to Our Intellectual Property

1. 37If we and our third-party licensors do not obtain and preserve protection for our respective intellectual property rights, our competitors may be able to take advantage of our (and our licensors’) development efforts to develop competing drugs
2. 38Our licensors may terminate or breach our existing or future license agreements, thereby reducing or preventing our ability to exclude competition; termination of such license agreements may also subject us to risk of patent infringement of patents to which we no longer have a license
3. 39As a matter of public policy regarding worldwide health concerns, there may be significant pressure on the U.S. government and other international governmental bodies to limit the scope of domestic and international patent protection for cancer treatments that prove successful
4. 40The patent protection we obtain and preserve for our product candidates may not be sufficient to provide us with any material competitive advantage
5. 41Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. If this occurs, our competitive position, business, financial condition, results of operations, and prospects would be materially harmed
6. 42Intellectual property disputes could require us to spend time and money to address such disputes and could limit our intellectual property rights
7. 43We may not be able to enforce our intellectual property rights throughout the world
8. 44Changes to the patent law in the U.S. and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
9. 45Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 46Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business

Risks Related to Our Business Operations and Industry

1. 47We have a limited operating history
2. 48Furthermore, if our business grows rapidly, our operational, managerial, legal, and financial resources will be strained. Our development will require continued improvement and expansion of our management team and our operational, managerial, legal, and financial systems and controls
3. 49If we lose key management leadership, and/or scientific personnel, and if we cannot recruit qualified employees, managers, directors, officers, or other significant personnel, it is highly likely that we will experience program delays and increases in compensation costs, and our business will be materially disrupted
4. 50We incur costs as a result of operating as a public company, and our management is required to devote substantial time to investor relations, information and communication to the public, and related compliance initiatives and corporate governance practices
5. 51Despite ongoing compliance training and periodic education, our employees and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could result in delays or terminations of our development programs and adversely affect our business
6. 52We are a smaller reporting company and we cannot be certain if the reduced disclosure requirements applicable to smaller reporting companies will make our common stock less attractive to investors
7. 53Competition and technological change may make our product candidates less competitive or obsolete
8. 54We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively
9. 55We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management
10. 56inability to retain key employees of any acquired businesses or for our current business based on changed circumstances
11. 57Our business and operations are vulnerable to computer system failures, cyber-attacks or deficiencies in our cybersecurity, which could increase our expenses, divert the attention of our management and key personnel away from our business operations and adversely affect our results of operations
12. 58Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business
13. 59If we, our contract research organizations (“CROs”) or our information technology (“IT”) vendors experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of personal data, we may face costs, significant liabilities, harm to our brand and business disruption
14. 60If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected
15. 61We have limited the liability of and indemnified our directors and officers
16. 62Future legislation or executive or private sector actions may increase the difficulty and cost for us to commercialize our products and adversely affect the prices obtained for such products
17. 63Even if we are able to commercialize any drug candidate, such drug candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business
18. 64Politically divided governmental actions and related political actions outside of government can impact the FDA’s role in the timely and effective review of new pharmaceutical products in the U.S. and our business may be adversely impacted
19. 65Effective collaboration with the FDA for the approval of drug candidates is a highly demanding process which can result in increased time and expense to gain approvals
20. 66Future tax reform measures may negatively impact our financial position
21. 67Foreign currency exchange rates may adversely affect our consolidated financial statements
22. 68Our anticipated operating expenses and capital expenditures over the next year are based upon our management’s estimates of possible future events. Actual amounts and the cost of new conditions could differ materially from those estimated by our management
23. 69The financial and operational projections that we may make from time to time are subject to inherent risks
24. 70Our present and potential future international operations may expose us to business, political, operational, and financial risks associated with doing business outside of the U.S
25. 71regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries
26. 72The ongoing trade tensions resulting from tariff discussions/impositions can materially and adversely impact our business
27. 73We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business
28. 74Existing and new investors will experience dilution as a result of future sales or issuances of our common stock, future exercises of the pre-funded warrants, and future option exercises under our 2016 Stock Incentive Plan and any amendments to the plan
29. 75Holders of the shares of our common stock will have no control of our operations or of decisions on major transactions
30. 76The stock price of our common stock may be volatile or may decline regardless of our operating performance
31. 77We may become involved in securities class action litigation that could divert management’s attention and harm our business
32. 78Substantial amounts of our outstanding shares may be sold into the market. If there are substantial sales of shares of our common stock or exercising of the pre-funded warrants, the price of our common stock could decline
33. 79Our ability to use our net operating loss carry-forwards and certain other tax attributes may be limited
34. 80If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
35. 81We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
36. 82There can be no assurance that we will ever provide liquidity to our investors through a sale of our Company
37. 83Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us difficult, limit attempts by our stockholders to replace or remove our current management or Board and adversely affect our stock price
38. 84provide that special meetings of our stockholders may be called only by our Board